drugset / Trial / NCT05292638
Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
RandomizedParallel-groupDouble-blindTreatment
Summary
A single-center, randomized, double-blind, single-injection, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501A in Glabellar lines.
Timeline
- Start
- 2022-02-15
- Primary completion
- 2022-06-10
- Completion
- 2022-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | — | Intramuscular |
| Subject | CKDB-501A | Protein / enzyme biologic | — | Intramuscular |
Indications
No indication recorded.